Home
Insights

Charles Rowland

Director at Generation Bio

Charlie has more than 30 years of biopharmaceutical industry experience and is currently a board member and strategic advisor for multiple biotechnology companies. He was most recently the president and chief executive officer (CEO) of Aurinia Pharmaceuticals, a clinical stage pharmaceutical company focused on the global lupus nephritis market. Prior to his tenure with Aurinia Pharmaceuticals, Charlie served as the vice president and chief financial officer (CFO) of ViroPharma, during which time the company grew into a global biopharmaceutical business with $500 million in annual revenues until it was acquired by Shire PLC for $4.2 billion. Before joining ViroPharma, he was executive vice president and CFO, as well as interim Co-CEO, for Endo Pharmaceuticals, a specialty pharmaceutical company with $1.3 billion in revenues. He previously held finance and operational positions of increasing responsibility at Biovail Pharmaceuticals, Breakaway Technologies, Pharmacia, Novartis and Bristol-Myers Squibb. Charlie currently serves as a member of the board of directors for Blueprint Medicines, Nabriva Therapeutics, Viking Therapeutics, Psioxus Therapeutics and Orchard Therapeutics with previous board appointments including Vitae Pharmaceuticals, BIND Therapeutics, Aurinia Pharmaceuticals and Idenix Pharmaceuticals, among others. He holds a Master of Business Administration from Rutgers University and a Bachelor of Science from Saint Joseph's University.

Roles

  • Director

    Current role

Social

By clicking "Continue" or continuing to use our site, you acknowledge that you accept our Privacy Policy and Terms of Use. We also use cookies to provide you with the best possible experience on our website.